INTRODUCTION
============

Thrombotic microangiopathies (TMAs) is a group of devastating diseases with very different aetiologies that share common characteristic features at presentation: microangiopathic haemolytic anaemia (MAHA) \[typified by anaemia, elevated lactate dehydrogenase (LDH), decreased serum haptoglobin and the presence of schistocytes in peripheral blood smear\], thrombocytopenia and organ damage, mainly the kidneys and the nervous system. The pathogenesis of TMA is based on a diffuse and severe vascular endothelial injury inducing characteristic histological lesions in affected organs: platelet thrombus occluding vessels, swelling and detachment of endothelial cells, and thickening of arterioles and capillaries \[[@gfw453-B1]\].

The most widely accepted classification establishes four categories of TMA: Shiga toxin-producing *Escherichia coli* haemolytic uraemic syndrome (STEC-HUS), thrombotic thrombocytopenic purpura (TTP), atypical haemolytic uraemic syndrome (aHUS) and secondary TMA \[[@gfw453-B1]\]. This last group includes a long list of clinical entities in which the occurrence of TMA has been repeatedly reported: drug treatments \[[@gfw453-B6], [@gfw453-B7]\], systemic diseases \[[@gfw453-B8]\], pregnancy/postpartum \[[@gfw453-B11], [@gfw453-B12]\], cancer \[[@gfw453-B7], [@gfw453-B13]\], haematopoietic stem cell and organ transplantation \[[@gfw453-B14], [@gfw453-B15]\], systemic infections \[[@gfw453-B16], [@gfw453-B17]\], glomerular diseases \[[@gfw453-B18], [@gfw453-B19]\], malignant hypertension \[[@gfw453-B20]\] and some very rare conditions such as intestinal lymphangiectasia \[[@gfw453-B21]\] or methylmalonicaciduria \[[@gfw453-B22]\]. The pathogenesis of STEC-HUS, TTP and aHUS has been largely clarified in recent years \[[@gfw453-B1]\], but the pathogenic pathways through which endothelial damage is induced in secondary TMA are not completely elucidated. It is generally accepted that in a significant number of patients within the group of secondary TMA there is a complement-related damage to the endothelium.

Eculizumab is a humanized monoclonal antibody that binds to complement C5 and prevents the formation of C5b-9, the membrane attack complex of the terminal complement pathway \[[@gfw453-B23]\]. The efficacy and safety of eculizumab in aHUS has been demonstrated by observational studies and prospective multicentre trials \[[@gfw453-B23], [@gfw453-B24]\].

Complement is a tightly controlled part of our innate immunity, fundamental among other things for the elimination of pathogens and cellular debris generated by normal tissue homeostasis. aHUS caused by pathogenic variants in the genes coding for complement components and regulators, or by autoantibodies against these proteins \[[@gfw453-B1], [@gfw453-B25], [@gfw453-B26]\], is referred here as primary aHUS, as suggested in the KDIGO Controversies Conference on aHUS and C3G \[[@gfw453-B27]\]. The genetic and acquired factors associated with primary aHUS cause complement dysregulation resulting in damage to the endothelial cells in the microvasculature of the kidneys and other organs. While complement dysregulation is central to the pathogenesis of primary aHUS, cumulative evidence suggests that complement hyperactivation and dysregulation also occurs in other forms of TMA apart from primary aHUS, including some patients with STEC-HUS and TTP, and may be particularly relevant in an important number of secondary TMA cases (reviewed in \[[@gfw453-B28]\]). We will refer to these cases of TMA as secondary aHUS. Further supporting the involvement of complement dysregulation in other forms of TMA apart from primary aHUS, individual case reports and small series of patients have been published in recent years showing a beneficial effect of eculizumab in cases of TMA associated with haematopoietic stem cell transplantation \[[@gfw453-B29], [@gfw453-B30]\], antiphospholipid syndrome \[[@gfw453-B31], [@gfw453-B32]\], systemic diseases \[[@gfw453-B33], [@gfw453-B34]\], pregnancy/postpartum \[[@gfw453-B35]\] and drug treatments \[[@gfw453-B36]\]. However, the small number of reported cases and the well-known tendency to preferentially publish those cases responding positively to new therapies prevents the generalization of such positive results.

To assess the potential benefit of eculizumab in this, so-called, secondary aHUS, we designed a collaborative retrospective study to identify these cases and revise those who had received eculizumab, independently of the aetiological factor causing the TMA and the final outcome of the eculizumab treatment.

MATERIALS AND METHODS
=====================

Study population and treatment
------------------------------

Patients with secondary aHUS treated with eculizumab were identified in 11 Spanish hospitals. Inclusion criteria were: (i) evidence of TMA, defined by the presence of low platelet count (\<150 × 10^9^/L), MAHA (low haemoglobin, LDH level above the upper limit of the normal range, decreased serum haptoglobin and presence of schistocytes in peripheral blood examination), negative Coombs test, normal activity of ADAMTS-13, negative Shiga toxin and impaired renal function fulfilling the criteria of acute kidney injury (AKI) \[[@gfw453-B39]\]; (ii) diagnosis of secondary TMA, based on the presence of a precipitating cause listed among the recognized aetiologies of secondary TMA \[[@gfw453-B5]\]; (iii) persistence of TMA and worsening of renal function despite the treatment of the TMA-precipitating trigger or disease; and (iv) treatment with eculizumab after previous treatments had failed. Exclusion criteria included previous episodes of TMA and, in renal transplant patients, the diagnosis of aHUS or C3 glomerulopathies in native kidneys. Patients fulfilling these inclusion and exclusion criteria were included in the study, independently of the TMA cause and patient's outcome after eculizumab treatment.

Eculizumab was administered in all the patients intravenously at a dose of 900 mg/week for 4 weeks, and then 1200 mg every 2 weeks. Plasmapheresis was discontinued in all the patients once they started eculizumab. All the patients received anti-meningococcal vaccination, according to label instructions, and received antibiotic prophylaxis. The duration of eculizumab therapy was decided by the treating physician, based on the patient's response and individual characteristics. Baseline data were considered to be the data coinciding with the detection of TMA. Follow-up was defined as the interval between the onset of eculizumab and the last visit or death.

Data collection
---------------

Data were compiled from the medical records of the participating centres using a uniform protocol and included age, gender, blood pressure and cause of TMA. Analytical variables included haemoglobin, platelet count, haptoglobin, LDH, presence of schistocytes in peripheral blood smear, Coombs test, ADAMTS-13 determination, Shiga toxin detection, serum creatinine (SCr), estimated glomerular filtration rate (eGFR), which was calculated using the four-variable Modification of Diet in Renal Disease equation, serum albumin and urinalysis. Results of the genetic analysis, performed in 22 patients were registered following a common protocol.

Treatments received before eculizumab, number of plasmapheresis sessions and the time interval between TMA onset and the initiation of eculizumab treatment were recorded, as well as the duration of eculizumab therapy and the cumulative dose administered to every patient. Complications occurring during plasmapheresis and eculizumab treatment, side effects, the occurrence of end-stage renal disease and deaths were also recorded.

Renal biopsies were performed in 18 patients and were reviewed for this study at every participating centre. Histological signs of TMA included glomerular and arteriolar thrombus, thickening of arteriolar walls, swelling and detachment of endothelial cells, widening of subendothelial space in glomerular capillaries and glomerular retraction.

Outcomes
--------

The primary outcome was TMA resolution, defined by a normalization of platelet count (\>150 × 10^9^/L), normalization of haemoglobin, disappearance of all the markers of MAHA and recovery of renal function, with a ≥25% reduction in SCr in two consecutive measurements for ≥4 weeks from the onset of eculizumab administration. Secondary outcomes were the normalization of platelet count and haemoglobin with the disappearance of MAHA markers, the number of patients requiring dialysis, a ≥25% and a ≥50% reduction from the onset of eculizumab in SCr and the number of patients with an eGFR ≥60 mL/min/1.73 m^2^ at latest follow-up.

Statistical analysis
--------------------

Continuous variables were expressed as median and interquartile (25th and 75th percentile) range. Categorical variables were expressed as frequencies and percentages. Categorical variables were compared with the Fisher's exact probability test and the medians were compared using the Mann--Whitney U test. To compare more than two categorical variables, the chi-square (χ^2^) test was used. Statistical analyses were performed with STATA software for Windows, version 12.0 (Statacorp LP, College Station, TX, USA) with two-sided hypothesis testing and a P \< 0.05 as the criteria for statistical significance.

Other methods
-------------

Complement genetic and molecular studies are described in detail in [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

RESULTS
=======

Clinical characteristics
------------------------

Twenty-nine patients were included in the study. Their main clinical characteristics at the onset of eculizumab treatment are summarized in Tables [1--4](#gfw453-T1){ref-type="table"}. MAHA and AKI were evident in all patients. Normal ADAMTS-13 activity was assessed in all patients, with a median value of 68% (60--78%). Stool analysis for Shiga toxin detection and Coombs test, performed in 14 and 24 patients, respectively, were negative. Fourteen patients (48%) were undergoing dialysis at the onset of eculizumab due to the severity of renal failure and/or volume expansion. Severe extrarenal manifestations were observed in 11 patients (38%): five patients presented with seizures, three had decreased level of consciousness, four headache and blurred vision, and one had dilated cardiomyopathy. Table 1Characteristics at the initiation of eculizumab treatmentPatients (*n* = 29)Age (years)[^a^](#tblfn2){ref-type="table-fn"}51.8  (36.2--59.6)Gender, no.  (%), male16  (55.2)Cause of aHUS, no.  (%)**Drug-induced15  (51.7)** Tacrolimus14  (93.3) Everolimus4  (26.7) Sirolimus1  (6.7)**Systemic disease8  (27.6)** SLE3  (37.5) Scleroderma2  (25) Vasculitis  (EGPA)2  (25) Antiphospholipid syndrome1  (12.5)**Other causes6  (20.7)** Pregnancy/postpartum2  (33.3) Cancer related2  (33.3) Acute humoral rejection renal transplant1  (16.7) Primary intestinal lymphangiectasia1  (16.7)Time from aHUS diagnosis to eculizumab treatment  (days)13  (7--26)Extrarenal manifestation, no.  (%)11  (37.9)Dialysis before eculizumab, no.  (%)14  (48.3)Laboratory findings SCr  (mg/dL)[^a^](#tblfn2){ref-type="table-fn"}4  (3.4--5.6) eGFR  (mL/min/1.73 m^2^)[^a^](#tblfn2){ref-type="table-fn"}13  (7.7--19.0)LDH  (mg/dL)[^a^](#tblfn2){ref-type="table-fn"}960  (570--1950) Haptoglobin  (mg/dL)[^a^](#tblfn2){ref-type="table-fn"}5  (0--12)Haemoglobin  (g/dL)[^a^](#tblfn2){ref-type="table-fn"}8.8  (8.1--9.9)Platelet count  (×1000/µL)[^a^](#tblfn2){ref-type="table-fn"}73  (51--113) Schystocites, no.  (%)28  (96.6)Follow-up  (months)[^a^](#tblfn2){ref-type="table-fn"}5.2  (4.2--14.1)[^1][^2]Table 2Drug-induced aHUSPatientAge (years), genderOffending drugTreatment before eculizumabPE no. of sessionsEculizumab (duration, no. of doses)Time from aHUS to eculizumab (days)Highest SCr (mg/dL) HD (Yes/No)Latest SCr (mg/dL)Follow-up (months)143, femaleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}DW + PE32 weeks, 243.8 No1.116.2263 femaleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}DW + PE1018 weeks, 11533.1 Yes2.05.9334, maleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}PE324 weeks, 14109.8 Yes2.66.7418, femaleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}DW + PE23 weeks, 3142.1 No29.6552, femaleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}DW--8 weeks, 6262.9 No1.28.3643, maleTacrolimus[^a^](#tblfn4){ref-type="table-fn"}DW + PE630 weeks, 17353.8 Yes1.116.2736, femaleEverolimus[^a^](#tblfn4){ref-type="table-fn"}DW + PE66 weeks, 594.2 No2.117.5860, maleTacrolimus[^b^](#tblfn5){ref-type="table-fn"}DW--4 weeks, 4533.4 Yes2.53.4967, maleTacrolimus, everolimus[^b^](#tblfn5){ref-type="table-fn"}DW + PE66 weeks, 5101.8 No2.01.71059, maleTacrolimus, everolimus[^b^](#tblfn5){ref-type="table-fn"}DW + PE510 weeks, 773.5 No2.04.81165, maleTacrolimus, everolimus[^b^](#tblfn5){ref-type="table-fn"}DW + PE62 weeks, 293.3 No2.44.51251, maleTacrolimus[^c^](#tblfn6){ref-type="table-fn"}DW + PE24 weeks, 4102.4 No0.62.91354, femaleTacrolimus, sirolimus[^c^](#tblfn6){ref-type="table-fn"}DW + PE73 weeks, 374.2 Yes1.21.51455, maleTacrolimus[^d^](#tblfn7){ref-type="table-fn"}DW + PE1218 weeks, 11273.0 No2.414.11542, femaleTacrolimus[^e^](#tblfn8){ref-type="table-fn"}DW + PE33 weeks, 3131.4 No0.517.0[^3][^4][^5][^6][^7][^8]Table 3aHUS associated with systemic diseasePatientAge (years), genderSystemic diseaseTreatment before eculizumabPE no. of sessionsEculizumab (duration, no. of doses)Time from aHUS to eculizumab (days)Highest SCr (mg/dL) HD (Yes/No)Latest SCr (mg/dL)Follow-up (months)1651, femaleSLE^a^CS + Cyc + Rtx + PE104 weeks, 4314.2 YesDialysis0.91716, femaleSLE^a^CS + MMF--10 weeks, 717.1 YesDialysis4.21852, femaleSLECS + Cyc + PE272 weeks, 2386.4 Yes4.24.01963, maleSclerodermaCS + Cyc + PE106 weeks, 5554.9 NoDialysis12.92056, maleSclerodermaCS + Mtx + PE108 weeks, 6253.7 No3.44.32152, maleEGPACS + Cyc--16 weeks, 1053.5 No2.34.32249, maleEGPACS + Cyc + PE2130 weeks, ongoing156.5 YesDialysis29.52338, malePrimary APS----14 weeks, 919.5 Yes3.44.4[^9]Table 4Other causes of secondary aHUSPatientAge (years), genderTMA causeTreatment before eculizumabPE no. of sessionsEculizumab (duration, no. of doses)Time from aHUS to eculizumab (days)Highest SCr (mg/dL) HD (Yes/No)Latest SCr (mg/dL)Follow-up (months)2427, femalePostpartumPE1546 weeks, 25244.1 No1.5132535, femalePostpartumPE816 weeks, 10175.9 Yes1.24.22661, maleCancer-related aHUS[^a^](#tblfn11){ref-type="table-fn"}Bilateral orchiectomy + PE210 weeks, 7311.1 Yes0.95.22773, maleCancer-related aHUS[^a^](#tblfn11){ref-type="table-fn"}Antiandrogentherapy + PE481 weeks, 4348.7 Yes1.022.62835, maleAcute humoral rejectionCS + IVIg + Rtx + PE53 weeks, 374.9 No1.610.72913, femalePrimary intestinal lymphangiectasiaPE464 weeks, ongoing215.4 Yes0.316.4[^10][^11]

Causes of aHUS and treatment before eculizumab
----------------------------------------------

As shown in Table [1](#gfw453-T1){ref-type="table"}, aHUS was induced by drugs in 15 patients, by systemic diseases in 8, by postpartum in 2, by cancer in 2, by acute humoral rejection in 1 and by primary intestinal lymphangiectasia in 1. All drug-induced aHUS corresponded to transplanted patients who had received a kidney graft (seven patients), lung (four patients), haematopoietic stem cells (two patients), liver (one patient) or heart (one patient) (Table [2](#gfw453-T2){ref-type="table"}). In seven patients with a kidney graft (\#1 to \#7), median interval between transplantation and aHUS detection was 14 days (7--20). Induction treatment consisted of corticosteroids, tacrolimus and mycophenolate mofetil in all of them. Four patients (\#1, \#2, \#3 and \#6) also received antithymocyte globulin.

The offending drug was tacrolimus (combined with everolimus in patients \#9, \#10 and \#11 and with sirolimus in patient \#13, Table [2](#gfw453-T2){ref-type="table"}) in all but one patient (Table [2](#gfw453-T2){ref-type="table"}), in whom aHUS was attributed to everolimus (patient \#7). Offending drugs were discontinued in all the patients but one (patient \#3), without TMA improvement (Table [2](#gfw453-T2){ref-type="table"}). In this patient (hyperimmunized recipient of a second transplant), tacrolimus was maintained due to the high risk of rejection.

Eculizumab was initiated after only two to three sessions of plasmapheresis in patients \#1, \#3, \#4 and \#12 with drug-induced aHUS (Table [2](#gfw453-T2){ref-type="table"}) due to the progressive deterioration in these cases of renal function and the persistence of severe extrarenal manifestations (seizures, blurred vision, decreased level of consciousness), as well as the appearance of plasmapheresis-related complications, transfusion-related reaction and bleeding in patients \#4 and \#12.

Systemic disease-related aHUS occurred in eight patients: systemic lupus erythematosus (SLE) in three, systemic scleroderma in two, eosinophilic granulomatosis with polyangiitis (EGPA) in two and primary antiphospholipid syndrome in one (Table [3](#gfw453-T3){ref-type="table"}). All the patients with systemic diseases developed aHUS in their native kidneys, with the exception of the patient with primary antiphospholipid syndrome, who presented aHUS 7 days after renal transplantation. In four out of eight patients (50%), aHUS was the first manifestation of the disease (patients \#16, \#17, \#19 and \#20). Patients with systemic diseases received different types of immunosuppressive treatments before eculizumab (Table [3](#gfw453-T3){ref-type="table"}).

Six patients presented a miscellany of secondary TMA causes: aHUS appearing after delivery in two patients, cancer-related aHUS in two (metastatic prostate cancer in both), aHUS associated with acute humoral rejection in a kidney transplant patient and with primary intestinal lymphangiectasia in another patient (Table [4](#gfw453-T4){ref-type="table"}). Antiandrogenic therapy, immunosuppressive anti-rejection treatments and antibiotics have been prescribed for prostate cancer, humoral rejection and intestinal lymphangiectasia, respectively.

Plasmapheresis was performed before the onset of eculizumab in 24 patients (83%), 13 with drug-induced aHUS, 5 with systemic diseases, 2 with postpartum aHUS, 2 with cancer-related aHUS, 1 with acute humoral rejection and 1 with primary intestinal lymphangiectasia (Tables [2--4](#gfw453-T2){ref-type="table"}). Complications related to the performance of plasmapheresis were transfusion-related reactions (five), deep vein thrombosis (two), bleeding (one) and hypotension (one).

Renal biopsies
--------------

Renal biopsies were performed in 18 patients (62%). Characteristic lesions of TMA were found in all of them. A renal biopsy was performed in six out of seven kidney transplant patients with drug-induced aHUS (patients \#2, \#3, \#4, \#5, \#6 and \#7). No lesions of antibody-mediated rejection (AMR) were found and C4d staining was negative in all of them. C3 glomerulopathy was diagnosed in patient \#11, on the basis of strong, isolated deposits of C3 in immunofluorescence studies. A membranoproliferative glomerulonephritis likely associated with hepatitis C virus infection was found in patient \#14 (Table [2](#gfw453-T2){ref-type="table"}). Among patients with aHUS associated with systemic diseases, a class IV-S (C) lupus nephritis with advanced glomerular and interstitial sclerosing lesions was found in two patients with SLE (patients \#16 and \#17, Table [3](#gfw453-T3){ref-type="table"}) and a class IV-G (A) lupus nephritis in the remaining SLE patient (patient \#18, Table [3](#gfw453-T3){ref-type="table"}). Patients with EGPA showed histological signs of vasculitis (fibrinoid necrosis in glomerular capillaries and arterioles with eosinophilic granulomas and interstitial infiltration by eosinophils) in addition to TMA. Renal biopsy in patient \#24, with postpartum aHUS, showed characteristic lesions of TMA with no tubular necrosis. Renal biopsy in the patient with acute humoral rejection-induced aHUS showed histological signs of acute humoral rejection (tubulitis, arteritis, C4d-positive staining) in addition to TMA.

Eculizumab treatment
--------------------

Eculizumab was started 13 (7--26) days after the onset of aHUS. In two patients (\#22 and \#29, Tables [2--4](#gfw453-T2){ref-type="table"}), investigators decided to maintain eculizumab after TMA resolution due to the identification of complement pathogenic variants in *CFH* and *CFHR1* (see 'Complement genetic studies' section). In 27 remaining patients, eculizumab was discontinued after 8 (3--18) weeks. The average number of eculizumab doses in these 27 patients was 6 (3--11).

Outcomes
--------

A rapid improvement in haematological and renal abnormalities after the onset of eculizumab was observed in 20 patients (69%) (Table [5](#gfw453-T5){ref-type="table"} and Figure [1](#gfw453-F1){ref-type="fig"}). The rate of response varied according to the aetiology of aHUS: 12/15 (80%) among drug-induced aHUS, 6/6 (100%) in postpartum, cancer-related, acute humoral rejection and intestinal lymphangiectasia, and 2/8 (25%) in aHUS associated with systemic diseases (Table [6](#gfw453-T6){ref-type="table"}). Among the latter, only one patient with EGPA and the patient with primary antiphospholipid syndrome showed TMA resolution after eculizumab treatment (Tables [2--4](#gfw453-T2){ref-type="table"}). The interval between eculizumab initiation and TMA resolution averaged 12 (7--17) days. All extrarenal manifestations showed a rapid and dramatic improvement. FIGURE 1Changes in (**A**) serum creatinine, (**B**) haemoglobin and (**C**) platelet count.Table 5Changes from baseline in haematological parameters and renal functionBaselineEculizumab onset4 weeks12 weeksLast follow-upPlatelet count  (×1000/µL)[^a^](#tblfn13){ref-type="table-fn"}65  (45--109)73  (51--113)166  (142--219)202  (157--254)182  (163--237)Haemoglobin  (g/dL)[^a^](#tblfn13){ref-type="table-fn"}8.7  (7.8--10.4)8.8  (8.1--9.9)10.5  (10--11.1)11  (10.2--12.3)11.8  (10.2--12.4)Haptoglobin  (mg/dL)[^a^](#tblfn13){ref-type="table-fn"}5  (0--5)5  (0--12)69  (32--115)118  (88--141)116  (86--135)Serum creatinine  (mg/dL)[^a^](#tblfn13){ref-type="table-fn"}3.5  (2.7--5.2)4.0  (3.4--5.6)2.3  (1.1--3.9)2.1  (1.1--3.5)2.0  (1.1--2.6)eGFR  (mL/min/1.73 m^2^)[^a^](#tblfn13){ref-type="table-fn"}18  (8.9--26)13  (7.7--19)27  (17--54)32  (26--71)34  (28--63)[^12][^13]Table 6OutcomesBaselineEculizumab onset4 weeks12 weeksLast follow-upTMA response, no.  (%)Total0  (0)0  (0)11  (37.9)19  (65.5)20  (68.9)Related to drugs0  (0)0  (0)6  (40)12  (80)12  (80)Related to systemic disease0  (0)0  (0)1  (12.5)1  (12.5)2  (25)Related to other causes0  (0)0  (0)4  (66.7)6  (100)6  (100)Patients undergoing dialysis, no.  (%)4  (13.8)14  (48.3)4  (13.8)4  (13.8)4  (13.8)Patients with ≥50% decrease from baseline SCr, no.  (%)0  (0)0  (0)10  (34.5)14  (48.3)15  (51.7)Patients with eGFR ≥60 mL/min/1.73 m^2^0  (0)0  (0)6  (20.7)10  (34.5)10  (34.5)[^14]

Resolution of haematological abnormalities with no improvement in renal function was observed in six patients (patients \#4, \#9, \#17, \#18, \#20 and \#22). In three cases (patients \#8, \#16 and \#19), both haematological abnormalities and renal function impairment persisted despite eculizumab treatment (Tables [2--4](#gfw453-T2){ref-type="table"}).

At the last follow-up, the number of patients requiring dialysis had decreased to 4 (13%), a ≥25% decrease in SCr was observed in 20 patients (69%), a ≥50% decrease in 15 (52%) and 10 patients (35%) had achieved an eGFR ≥60 mL/min/1.73 m^2^.

No differences in baseline characteristics were observed between responder and non-responder patients, but there was a significantly higher number of patients with aHUS associated with systemic diseases among non-responders. Interestingly, the duration of eculizumab treatment was significantly longer in responder patients and there was a non-significant trend towards a longer interval between aHUS diagnosis and onset of eculizumab in non-responder patients (Table [7](#gfw453-T7){ref-type="table"}). Table 7Differences between responder and non-responder patientsResponders  (*n* = 20)Non-responders  (*n* = 9)PAge  (years)[^a^](#tblfn16){ref-type="table-fn"}47.4  (35.9--57.5)51.9  (49.9--60.1)0.57Gender, no.  (%), male11  (55.0)5  (55.6)1Baseline SCr  (mg/dL)[^a^](#tblfn16){ref-type="table-fn"}3.4  (2.8--4.5)3.4  (1.8--6.2)0.75SCr at the onset of Eculizumab  (mg/dL)[^a^](#tblfn16){ref-type="table-fn"}^,b^3.8  (3.2--5.4)4.5  (3.4--6.7)0.82Dialysis, no.  (%)[^b^](#tblfn17){ref-type="table-fn"}9  (45)5  (55.6)0.70Haemoglobin  (g/dL)[^a^](#tblfn16){ref-type="table-fn"}^,b^9.0  (8.1--10)8.3  (7.7--104)0.65Platelet count  (×1000/µL)[^a^](#tblfn16){ref-type="table-fn"}^,b^78  (51--138)61  (29--80)0.25Cause of aHUS, no.  (%)0.004Systemic disease2  (25)6  (75)Drug induced12  (80)3  (20)Other causes6  (100)0  (0)Plasma exchange, no.  (%)17  (85)7  (77.8)0.50Time between aHUS and eculizumab  (days)[^a^](#tblfn16){ref-type="table-fn"}9.5  (6--22.5)25  (14--38)0.059Eculizumab duration  (weeks)[^a^](#tblfn16){ref-type="table-fn"}11.6  (4--24.7)4.4  (3--8.4)0.003[^15][^16][^17]

Complement genetic studies
--------------------------

Comprehensive complement studies were performed in 22/29 patients ([Supplementary Table](#sup1){ref-type="supplementary-material"}). These include western blot analyses and quantification of components, search for anti-Factor H (FH) autoantibodies and genetic screenings to identify pathogenic variants and copy number variations. Only two patients carry pathogenic variants. Patient \#22, affected by EGPA, carries two pathogenic changes in *CFHR1* (L290S and A296V) resulting in a mutant FHR-1 protein that competes with FH regulation on endothelial surfaces, and patient \#29, affected by intestinal lymphangiectasia, who presents a pathogenic variant in *CFH* (C597\*) that results in a partial FH deficiency. Patients \#11 and \#12 carry anti-FH autoantibodies, but presented normal C3 levels and do not have the *CFHR3--CFHR1* deletion, suggesting that these anti-FH autoantibodies may not be functionally relevant in the context of aHUS. Finally, some patients carry genetic variants in complement genes with unknown functional significance that were considered non-pathogenic.

Safety
------

Eculizumab was well tolerated. Serious infections occurred in two transplanted patients during eculizumab administration (prostatic abscess in one, herpes zoster infection in the other) but they were likely related to immunosuppressive treatment and resolved with appropriate treatments.

DISCUSSION
==========

Our study shows that eculizumab is an effective treatment for severe cases of secondary aHUS. In 20/29 eculizumab-treated patients (69%), there was a normalization of haemoglobin and platelet count together with a renal function improvement of at least a ≥25% reduction in SCr from the onset of eculizumab treatment. Renal function recovery was remarkable, allowing the discontinuation of dialysis in 10/14 patients. A decrease ≥50% in SCr was observed in 15 patients, and 10 patients (35%) showed an eGFR ≥60 mL/min/1.73 m^2^ at the last follow-up. Eculizumab has been reported to be beneficial in individual cases or small series of secondary TMA \[[@gfw453-B29]\], haematopoietic stem cell transplantation-induced aHUS being the entity in which the effects of eculizumab treatment have been more extensively documented \[[@gfw453-B29], [@gfw453-B30]\]. Our study is the first to confirm these positive effects in a relatively large series of secondary aHUS patients.

TMA responses after eculizumab treatment were particularly remarkable in patients with drug-induced aHUS (80% of TMA resolution) and in a miscellaneous group of secondary aHUS that included postpartum, cancer, acute humoral rejection and intestinal lymphangiectasia (100%). Although many patients with drug-induced aHUS show a rapid resolution after withdrawal of the offending drug, TMA can persist in others, requiring additional therapeutic measures because of life-threatening organ involvement or progressive renal impairment \[[@gfw453-B7], [@gfw453-B40]\]. Plasmapheresis, immunosuppression and, in a few patients, eculizumab \[[@gfw453-B36]\] have been tried in these resistant cases. Our results confirm that eculizumab is very effective to rapidly resolve TMA and improve renal function in this type of resistant drug-induced secondary aHUS.

Tacrolimus was the most common offending drug among our patients with drug-induced aHUS. Although tacrolimus discontinuation likely collaborated in TMA resolution, the rapid and dramatic improvement associated with eculizumab administration suggests a direct effect of complement blockade in TMA response in these patients. On the other hand, AMR in renal transplant patients can present features of TMA in renal biopsies and some reports have suggested a beneficial effect of eculizumab in AMR \[[@gfw453-B41]\]. However, no lesions of AMR were observed in the renal biopsies of our kidney transplant patients with drug-induced aHUS and C4d staining was negative in all of them.

On the contrary, our results show limited benefit of eculizumab administration in patients with systemic diseases (25% of TMA responses). Only one patient with primary antiphospholipid syndrome and another with ANCA vasculitis responded to eculizumab, whereas patients with SLE (three), scleroderma (two) and ANCA vasculitis (one) did not. These data do not agree with the eculizumab benefits reported in anecdotic cases of scleroderma-like syndrome and lupus nephritis complicated with aHUS \[[@gfw453-B33], [@gfw453-B34]\], but it should be stressed that our patients with SLE, scleroderma and ANCA vasculitis presented severe lesions in their renal biopsies at the initiation of eculizumab treatment.

Patients included in the study were treated according with the condition triggering TMA (discontinuation of the offending drug in drug-induced cases, immunosuppressive therapy in systemic diseases and humoral rejection, antitumoral treatment in cancer-related cases), and plasmapheresis was performed in 24 patients (83%) before initiation of eculizumab treatment. Despite these measures, renal function continued to deteriorate in all the patients and, at the time of eculizumab initiation, 14 patients (48%) were requiring dialysis. Persistent severe anaemia and thrombocytopenia was present in all patients (Table [1](#gfw453-T1){ref-type="table"}). Eculizumab rapidly resulted in the responder patients (20/29) in an improvement of renal function and the disappearance of all haematological abnormalities (Table [5](#gfw453-T5){ref-type="table"} and Figure [1](#gfw453-F1){ref-type="fig"}). Among the non-responders, the haematological abnormalities disappeared with eculizumab in 6/9 patients, although none of them showed a substantial renal function recovery. Extrarenal manifestations showed a rapid resolution after eculizumab initiation. Particularly dramatic was the rapid disappearance of life-threatening neurological complications (seizures, coma) in patients \#12, \#13, \#15, \#19, \#20 and \#22.

Complement is activated in several types of TMA other than primary aHUS \[[@gfw453-B28]\]. In STEC-HUS, Shiga toxin upregulates the membrane adhesion molecule P-selectin, which binds C3b and activates the complement alternative pathway (AP) \[[@gfw453-B42], [@gfw453-B43]\]. Low C3 and increased sC5b-9 have been reported in most severe cases of STEC-HUS \[[@gfw453-B44], [@gfw453-B45]\]. In TTP, levels of complement activation markers correlated with disease activity and deposition of C3 and C5b-9 have been demonstrated in endothelial cells \[[@gfw453-B46], [@gfw453-B47]\]. Interestingly, some patients with STEC-HUS and TTP not responding to plasmapheresis have been successfully treated with eculizumab \[[@gfw453-B48], [@gfw453-B49]\]. Regarding drug-induced aHUS, it has been shown that endothelial cells exposed to calcineurin inhibitors release microparticles that activate the AP \[[@gfw453-B50]\]. Inflammatory conditions, platelet-derived microparticles and blood coagulation proteins induce complement activation, which in turn increments endothelial damage and microvascular thrombosis \[[@gfw453-B51], [@gfw453-B52]\].

Prospective studies with eculizumab in primary aHUS have shown a significant inverse correlation between the delay in the onset of the treatment and the degree of renal function recovery \[[@gfw453-B24]\]. As shown in Table [7](#gfw453-T7){ref-type="table"}, an almost significant trend towards a longer delay in eculizumab therapy and a significantly shorter duration of treatment were observed among our non-responder patients. Further studies are needed to confirm whether an earlier treatment with eculizumab or a longer administration are associated with more positive responses and a greater recovery of renal function in patients with these secondary forms of aHUS.

Comprehensive complement molecular and genetic studies were performed in 22 patients, but pathogenic variants were found only in two patients ([Supplementary Table](#sup1){ref-type="supplementary-material"}). With the exception of these two patients (\#22 and \#29), eculizumab was discontinued after a median of 8 weeks, with no patients showing TMA relapses.

Tolerance to eculizumab was excellent with no important side effects recorded. Infectious complications coincidental with eculizumab administration in transplanted patients were attributable to immunosuppressive therapy.

Our study has the limitations inherent to its retrospective design, with a possible bias in the selection of patients and absence of a control group not treated with eculizumab. On the other hand, it has major strengths: the number of recruited patients is large and the work-up tests to exclude other types of TMA was complete, with ADAMTS-13 activity measured in all the patients and the presence of Shiga toxin ruled out in all the cases with gastrointestinal symptoms. Furthermore, renal biopsies and comprehensive genetic and molecular studies were performed in most patients. All the patients received the specific treatment for their aHUS aetiology and plasmapheresis was performed in most of them before eculizumab treatment.

Our findings are consistent with the observation that both primary aHUS, associated with genetic and acquired complement abnormalities, and secondary aHUS are characterized by complement dysregulation. In addition, they suggest that while complement dysregulation is constitutive in the first condition, it is likely temporary in the second and, therefore, both conditions should be considered differently regarding long-term treatment. Based on the results of this study, we suggest that eculizumab could be the first-line treatment in aggressive cases of secondary aHUS who do not respond to other therapies and that a rapid administration of eculizumab would enable an efficient recovery of renal function and complement normalization. Prospective studies are needed to corroborate these findings and to define the ideal duration of eculizumab treatment in secondary aHUS.
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[^1]: eGFR, estimated glomerular filtration rate; EGPA, eosinophilic granulomatosis with polyangiitis; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome; LDH, lactate dehydrogenase.

[^2]: Median  (25th--75th percentile).

[^3]: DW, drug withdrawn; HD, haemodialysis (Yes/No); PE, plasma exchange; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.

[^4]: Kidney transplant.

[^5]: Lung transplant.

[^6]: Haematopoietic stem cell transplantation.

[^7]: Liver transplant.

[^8]: Heart transplant.

[^9]: ^a^aHUS, atypical haemolytic uraemic syndrome; APS, Antiphospholip syndrome; CS, corticosteroids; Cyc, cyclophosphamide; EGPA, eosinophilic granulomatosis with polyangiitis; HD, Hemodialysis (Yes/No); Mtx, methotrexate; MMF, mycophenolate mofetil; ND, not done; PE, plasma exchange; Rtx, rituximab; SCr, serum creatinine; SLE, systemic lupus erythematosus.

[^10]: CS, corticosteroids; HD, haemodialysis; IVIg, intravenous immunoglobulin; PE, plasma exchange; Rtx, rituximab; SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.

[^11]: Cancer-related aHUS:metastatic prostate cancer.

[^12]: eGFR, glomerular filtrate rate.

[^13]: Median  (25th--75th percentile).

[^14]: TMA, thrombotic microangiopathy; eGFR, glomerular filtrate rate; SCr, serum creatinine.

[^15]: SCr, serum creatinine; aHUS, atypical haemolytic uraemic syndrome.

[^16]: Median  (25th--75th percentile).

[^17]: At the onset of eculizumab.
